Non-invasive prenatal test iSAFE NIPT
A highly accurate, fast, and accessible genetic test performed using digital PCR. From the 12th week of pregnancy, it analyses cell-free fetal DNA and helps assess the risk of the most common chromosomal abnormalities.
Genetic information – an early step in safeguarding your baby’s health
About 1 in 240 newborns are born with chromosomal abnormalities that may affect a child’s development or health. Although risk increases with parental age, younger couples can also face uncertainty. From week 12 of pregnancy, iSAFE NIPT helps assess fetal genetic health risks in advance using cell-free DNA analysis – accurately, quickly, and without risk to the pregnancy.
How does the iSAFE NIPT test work?
iSAFE NIPT is a non-invasive prenatal test performed using advanced digital PCR technology. It analyses cell-free fetal DNA circulating in the mother’s blood from the 12th week of pregnancy and enables highly accurate assessment of the risk of the most common chromosomal abnormalities.
Digital PCR divides the sample into thousands of tiny reactions in which DNA is amplified separately – achieving extremely high sensitivity even when the fetal DNA fraction is low. The test identifies:
Trisomy 21 (Down syndrome)
Trisomy 18 (Edwards syndrome)
Trisomy 13 (Patau syndrome)
Sex chromosome aneuploidies (e.g., Turner or Klinefelter syndromes)
Fetal sex (at parents’ request)
A calmer pregnancy begins with knowing
iSAFE NIPT helps reduce uncertainty and stress during pregnancy – a safe, fast, and accurate way to assess the risk of the most common genetic abnormalities already in the first trimester.
Fast results – within just 5 business days
Unlike many other NIPT tests, iSAFE provides results particularly quickly, so you don’t have to wait long in uncertainty.
Very high accuracy
Digital PCR technology enables highly precise detection even when only small amounts of cell-free fetal DNA are present, ensuring reliable results.
Safe and non-invasive
The test is performed from the mother’s blood, with no risk to the fetus – an comfortable and safe option for families.
Widely applicable for all pregnant women
Suitable for pregnant women of any age or risk group – both in a first pregnancy and in subsequent pregnancies.
When and for whom is the test recommended?
For first-time pregnant women
Enables quick and safe assessment of genetic abnormality risk at an early stage of pregnancy.
For older pregnant women
As maternal age increases, so does the likelihood of chromosomal changes – iSAFE helps reduce uncertainty and supports informed decisions.
For pregnant women who value additional information
If you want to avoid invasive procedures or learn the baby’s sex early, iSAFE offers an accurate and fast alternative.
For couples who feel anxious about the baby’s health
iSAFE helps provide emotional reassurance and confidence throughout the pregnancy – important for every family.
iSAFE NIPT reliability: accuracy and quality metrics
iSAFE uses digital PCR technology, which partitions DNA into thousands of small reactions and precisely detects even subtle genetic changes. The test’s sensitivity and specificity are comparable to the most advanced genetic screening methods, while results are delivered faster and at lower cost.
99% accuracy
Screens for trisomies of chromosomes 21, 18, and 13
Genetically informed fetal health screening
Take the iSAFE NIPT test and receive reliable information about your baby’s health – quickly and without invasive procedures.
For Specialists
All key information in one place – from the genes analysed to test accuracy and clinical value. This section is intended for specialists who want a detailed understanding of the test rationale, structure, and practical applications.
Chromosomal abnormalities are detected in approximately 1 in 240 newborns, and the likelihood increases with parental age. iSAFE NIPT enables early, non-invasive identification of the most common fetal genetic abnormalities, making it particularly relevant for expecting couples who want to make timely, informed decisions.
The iSAFE test is performed using modern digital polymerase chain reaction (digital PCR). The sample is partitioned into thousands of small reactions, each carrying out separate DNA amplification. This methodology achieves exceptionally high sensitivity and accuracy, even when the amount of cell-free fetal DNA in the sample is very low.
The test can identify the most common genetic conditions:
- Trisomy 21 (Down syndrome)
- Trisomy 18 (Edwards syndrome)
- Trisomy 13 (Patau syndrome)
- Sex chromosome aneuploidies (e.g., Turner, Klinefelter, and other syndromes)
Additionally, at the parents’ request, the baby’s sex can be determined.
Unlike traditional NIPT tests based on next-generation sequencing (NGS), iSAFE NIPT does not require complex laboratory infrastructure. This helps ensure cost-effectiveness, faster turnaround times, and greater accessibility in healthcare settings.
